Lymphoma-CLL/SLL
Primary Site | Histology |
---|---|
C000-C440, C442-C689, C691-C694, C698-C809 | 9823 |
Notes
9823 (EXCEPT C441, C690, C695-C696) **Note 1:** The following sources were used in the development of this schema * SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998) (https://seer.cancer.gov/archive/manuals/EOD10Dig.3rd.pdf) * SEER Summary Staging Manual-2000: Codes and Coding Instructions (https://seer.cancer.gov/tools/ssm/) * Collaborative Stage Data Collection System, version 02.05: https://cancerstaging.org/cstage/Pages/default.aspx * Chapter 79 *Hodgkin and Non-Hodgkin Lymphomas*, in the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing. Used with permission of the American College of Surgeons, Chicago, Illinois. * Chapter 80 *Pediatric Hodgkin and Non-Hodgkin Lymphomas*, in the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing. Used with permission of the American College of Surgeons, Chicago, Illinois. **Note 2:** See the following schema for the listed primary sites * C441, C690, C695-C696 (9823): *Lymphoma Ocular Adnexa* **Note 3:** Chronic lymphocytic leukemia/Chronic lymphocytic lymphoma (CLL/SLL) is always coded as a lymphoma. **Note 4:** The Cotswold modification of the Ann Arbor staging system (used in AJCC 6th and 7th editions) has been updated to the *Lugano classification*. The *Lugano classification* includes an E suffix for lymphoma with either localized extralymphatic presentations (Stage IE) or by contiguous spread from nodal disease (Stage IIE). A change from the Cotswold modification of the Ann Arbor Staging System, E lesions do not apply to patients with Stage III nodal disease; or any patient with nodal disease above and below the diaphragm with concurrent contiguous extralymphatic involvement (Stage IV), which was previously Stage IIIE. **Note 5:** In addition to coding EOD Primary Tumor, the following data items are also needed to assign a stage group for CLL/SLL. * Adenopathy * Anemia * Lymphocytosis * Organomegaly * ThrombocytopeniaData Items
Name | Default Value | Used for Staging | NAACCR Item | Required By | Metadata |
---|---|---|---|---|---|
Year of Diagnosis | <BLANK> | No | NAACCR #390 | None | |
Primary Site | <BLANK> | Yes | NAACCR #400 | None | |
Histology | <BLANK> | Yes | NAACCR #522 | None | |
Tumor Size Clinical | <BLANK> | No | NAACCR #752 | None | |
Tumor Size Pathological | <BLANK> | No | NAACCR #754 | None | |
Tumor Size Summary | 999 | No | NAACCR #756 | None | |
Regional Nodes Positive | 99 | No | NAACCR #820 | None | |
Regional Nodes Examined | 99 | No | NAACCR #830 | None | |
EOD Primary Tumor | 999 | Yes | NAACCR #772 | None | |
EOD Regional Nodes | 888 | Yes | NAACCR #774 | None | |
EOD Mets | 88 | Yes | NAACCR #776 | None | |
SS2018 | <BLANK> | No | NAACCR #764 | None | |
Grade Clinical | 8 | No | NAACCR #3843 | CCCR/Canada COC NPCR SEER |
SSDI |
Grade Pathological | 8 | No | NAACCR #3844 | CCCR/Canada COC NPCR SEER |
SSDI |
Grade Post Therapy | <BLANK> | No | NAACCR #3845 | CCCR/Canada COC NPCR SEER |
SSDI |
B Symptoms | 8 | No | NAACCR #3812 | CCCR/Canada COC NPCR SEER |
SSDI |
HIV Status | 8 | No | NAACCR #3859 | COC SEER |
SSDI |
Intern Prognostic Index | X8 | No | NAACCR #3896 | COC SEER |
SSDI |
Adenopathy | 9 | No | NAACCR #3804 | CCCR/Canada COC NPCR SEER |
SSDI |
Organomegaly | 9 | No | NAACCR #3907 | CCCR/Canada COC NPCR SEER |
SSDI |
Anemia | 9 | No | NAACCR #3811 | CCCR/Canada COC NPCR SEER |
SSDI |
Lymphocytosis | 9 | No | NAACCR #3885 | CCCR/Canada COC NPCR SEER |
SSDI |
Thrombocytopenia | 9 | No | NAACCR #3933 | CCCR/Canada COC NPCR SEER |
SSDI |
Initial Context
Outputs
Name | Default Value | Description | NAACCR Item | Metadata |
---|---|---|---|---|
Schema ID | 00795 |
NAACCR #3800
None |
None | |
Derived Version | {{ctx_alg_version}} | None | None | |
Derived Summary Stage 2018 | 9 |
NAACCR #762
None |
None |